10 20 30 40 50 60 70 80 1S1X - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER TRANSFERASE 07-JAN-04 1S1X
TITLE CRYSTAL STRUCTURE OF V108I MUTANT HIV-1 REVERSE TITLE 2 TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
COMPND MOL_ID: 1; COMPND 2 MOLECULE: REVERSE TRANSCRIPTASE; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 SYNONYM: HIV-1 RT; COMPND 6 EC: 2.7.7.49; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: REVERSE TRANSCRIPTASE; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: P51; COMPND 13 SYNONYM: HIV-1 RT; COMPND 14 EC: 2.7.7.49; COMPND 15 ENGINEERED: YES; COMPND 16 MUTATION: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: HXB2; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PKK233-2; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 12 ORGANISM_TAXID: 11676; SOURCE 13 GENE: POL; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: HXB2; SOURCE 17 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PKK233-2
KEYWDS HIV-1 REVERSE TRANSCRIPTASE, AIDS, NNRTI, NEVIRAPINE, DRUG KEYWDS 2 RESISTANCE MUTATIONS, TRANSFERASE
EXPDTA X-RAY DIFFRACTION
AUTHOR J.REN,C.E.NICHOLS,P.P.CHAMBERLAIN,D.K.STAMMERS
REVDAT 2 24-FEB-09 1S1X 1 VERSN REVDAT 1 29-JUN-04 1S1X 0
JRNL AUTH J.REN,C.E.NICHOLS,P.P.CHAMBERLAIN,K.L.WEAVER, JRNL AUTH 2 S.A.SHORT,D.K.STAMMERS JRNL TITL CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASES JRNL TITL 2 MUTATED AT CODONS 100, 106 AND 108 AND MECHANISMS JRNL TITL 3 OF RESISTANCE TO NON-NUCLEOSIDE INHIBITORS JRNL REF J.MOL.BIOL. V. 336 569 2004 JRNL REFN ISSN 0022-2836 JRNL PMID 15095972 JRNL DOI 10.1016/J.JMB.2003.12.055
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH P.P.CHAMBERLAIN,J.REN,C.E.NICHOLS,L.DOUGLAS, REMARK 1 AUTH 2 J.LENNERSTRAND,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF ZIDOVUDINE- OR REMARK 1 TITL 2 LAMIVUDINE-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REMARK 1 TITL 3 TYPE 1 REVERSE TRANSCRIPTASES CONTAINING MUTATIONS REMARK 1 TITL 4 AT CODONS 41, 184, AND 215 REMARK 1 REF J.VIROL. V. 76 10015 2002 REMARK 1 REFN ISSN 0022-538X REMARK 1 DOI 10.1128/JVI.76.19.10015-10019.2002 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.REN,C.NICHOLS,L.BIRD,P.CHAMBERLAIN,K.L.WEAVER, REMARK 1 AUTH 2 S.A.SHORT,D.I.STUART,D.K.STAMMERS REMARK 1 TITL STRUCTURAL MECHANISMS OF DRUG RESISTANCE FOR REMARK 1 TITL 2 MUTATIONS AT CODONS 181 AND 188 IN HIV-1 REVERSE REMARK 1 TITL 3 TRANSCRIPTASE AND THE IMPROVED RESILIENCE OF REMARK 1 TITL 4 SECOND GENERATION NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MOL.BIOL. V. 312 795 2001 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.2001.4988 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.H.CHAN,J.S.HONG,R.N.HUNTER III,G.F.ORR,J.R.COWAN, REMARK 1 AUTH 2 D.B.SHERMAN,S.M.SPARKS,B.E.REITTER,C.W.ANDREWS III, REMARK 1 AUTH 3 R.J.HAZEN,M.ST CLAIR,L.R.BOONE,R.G.FERRIS, REMARK 1 AUTH 4 K.L.CREECH,G.B.ROBERTS,S.A.SHORT,K.WEAVER,R.J.OTT, REMARK 1 AUTH 5 J.REN,A.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 2-AMINO-6-ARYLSULFONYLBENZONITRILES AS REMARK 1 TITL 2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OF REMARK 1 TITL 3 HIV-1 REMARK 1 REF J.MED.CHEM. V. 44 1866 2001 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM0004906 REMARK 1 REFERENCE 4 REMARK 1 AUTH J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL STRUCTURAL BASIS FOR THE RESILIENCE OF EFAVIRENZ REMARK 1 TITL 2 (DMP-266) TO DRUG RESISTANCE MUTATIONS IN HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE REMARK 1 REF STRUCTURE V. 8 1089 2000 REMARK 1 REFN ISSN 0969-2126 REMARK 1 DOI 10.1016/S0969-2126(00)00513-X REMARK 1 REFERENCE 5 REMARK 1 AUTH J.REN,C.NICHOLS,L.E.BIRD,T.FUJIWARA,H.SUGINOTO, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL BINDING OF THE SECOND GENERATION NON-NUCLEOSIDE REMARK 1 TITL 2 INHIBITOR S-1153 TO HIV-1 REVERSE TRANSCRIPTASE REMARK 1 TITL 3 INVOLVES EXTENSIVE MAIN CHAIN HYDROGEN BONDING REMARK 1 REF J.BIOL.CHEM. V. 275 14316 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.19.14316 REMARK 1 REFERENCE 6 REMARK 1 AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD, REMARK 1 AUTH 2 S.IKEMIZU,M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART, REMARK 1 AUTH 3 D.K.STAMMERS REMARK 1 TITL PHENETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE REMARK 1 TITL 2 INHIBITORS OF HIV-1 AND HIV-2 REVERSE REMARK 1 TITL 3 TRANSCRIPTASES. STRUCTURAL AND BIOCHEMICAL ANALYSES REMARK 1 REF J.BIOL.CHEM. V. 275 5633 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.8.5633 REMARK 1 REFERENCE 7 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 THIAZOLOISOINDOLINONE NON-NUCLEOSIDE INHIBITORS TO REMARK 1 TITL 3 HIV-1 REVERSE TRANSCRIPTASE AND COMPARISON WITH REMARK 1 TITL 4 MODELING STUDIES REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 8 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH REMARK 1 TITL 2 IMPROVED ACTIVITY AGAINST DRUG-RESISTANT HIV REMARK 1 TITL 3 MUTANTS REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 9 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE REMARK 1 TITL 2 IN COMPLEX WITH CARBOXANILIDE DERIVATIVES REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 10 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY, REMARK 1 AUTH 2 J.KEELING,C.K.ROSS,B.A.LARDER,D.I.STUART, REMARK 1 AUTH 3 D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE REMARK 1 TITL 2 MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE CAN REMARK 1 TITL 3 INDUCE LONG RANGE CONFORMATIONAL CHANGES REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 1 REFERENCE 11 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.GARMAN,D.O.SOMERS,C.K.ROSS, REMARK 1 AUTH 2 E.Y.JONES,D.K.STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT REMARK 1 TITL 2 CELL OF HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON REMARK 1 TITL 3 DEHYDRATION REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 DOI 10.1107/S0907444998004284 REMARK 1 REFERENCE 12 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX REMARK 1 TITL 2 BETWEEN HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN REMARK 1 TITL 4 RESISTANCE MUTATIONS FOR THIS NON-NUCLEOSIDE REMARK 1 TITL 5 INHIBITOR REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.94.8.3984 REMARK 1 REFERENCE 13 REMARK 1 AUTH A.L HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES, REMARK 1 AUTH 2 C.K.ROSS,T.MIYASAKA,R.T.WALKER,H.TANAKA, REMARK 1 AUTH 3 D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH REMARK 1 TITL 2 INHIBITORS OF THE HEPT SERIES REVEAL REMARK 1 TITL 3 CONFORMATIONAL CHANGES RELEVANT TO THE DESIGN OF REMARK 1 TITL 4 POTENT NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM960056X REMARK 1 REFERENCE 14 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE REMARK 1 TITL 2 COMPLEXED WITH 9-CHLORO-TIBO: LESSONS FOR REMARK 1 TITL 3 INHIBITOR DESIGN REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 15 REMARK 1 AUTH J.REN,R.M.ESNOUF,E.GARMAN,D.O.SOMERS,C.K.ROSS, REMARK 1 AUTH 2 I.KIRBY,J.KEELING,G.DARBY,E.Y.JONES,D.I.STUART, REMARK 1 AUTH 3 D.K.STAMMERS REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 16 REMARK 1 AUTH R.M.ESNOUF,J.REN,C.K.ROSS,E.Y.JONES,D.K.STAMMERS, REMARK 1 AUTH 2 D.I.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE REMARK 1 TITL 2 TRANSCRIPTASE BY NON-NUCLEOSIDE INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 17 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY, REMARK 1 AUTH 2 J.E.WILSON,M.NORMAN,J.REN,R.M.ESNOUF,E.GARMAN, REMARK 1 AUTH 3 E.Y.JONES,D.I.STUART REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE REMARK 1 TITL 2 DIFFRACTING TO 2.2 A RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1994.1604
REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.0 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.57 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1680108.090 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.6 REMARK 3 NUMBER OF REFLECTIONS : 27001 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.235 REMARK 3 FREE R VALUE : 0.295 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT : 1313 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.008 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.80 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.90 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 72.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1881 REMARK 3 BIN R VALUE (WORKING SET) : 0.4410 REMARK 3 BIN FREE R VALUE : 0.4920 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 85 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.053 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7749 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 20 REMARK 3 SOLVENT ATOMS : 21 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 80.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 84.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -11.30000 REMARK 3 B22 (A**2) : -23.80000 REMARK 3 B33 (A**2) : 35.10000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.40 REMARK 3 ESD FROM SIGMAA (A) : 0.50 REMARK 3 LOW RESOLUTION CUTOFF (A) : 30.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.55 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.62 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.50 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 23.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.00 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 4.150 ; 4.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 6.900 ; 6.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 5.890 ; 5.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 9.450 ; 8.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.29 REMARK 3 BSOL : 33.67 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER_REP.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE STANDARD CRYSTALLOGRAPHIC REMARK 3 RESIDUAL WAS USED AS TARGET FUNCTION IN THE FINAL ROUND OF REMARK 3 REFINEMENT INCLUDING ALL THE REFLECTIONS INSTEAD OF THE MLF IN REMARK 3 THE PREVIOUS ROUNDS OF REFINEMENT WITH CROSS-VALIDATION, WHICH REMARK 3 RESULTED IN THE R-FACTOR FOR ALL DATA BEING SMALLER THAN R- REMARK 3 WORKING.
REMARK 4 REMARK 4 1S1X COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 13-JAN-04. REMARK 100 THE RCSB ID CODE IS RCSB021263.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-OCT-99 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.978 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 27049 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 10.270 REMARK 200 R MERGE (I) : 0.11500 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 20.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.2 REMARK 200 DATA REDUNDANCY IN SHELL : 5.07 REMARK 200 R MERGE FOR SHELL (I) : 0.52300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.76 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.52 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 5, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 277K
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 69.20000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 36.40000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 54.50000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 36.40000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 69.20000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 54.50000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5820 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 45100 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO A 1 REMARK 465 LYS A 66 REMARK 465 ASP A 67 REMARK 465 SER A 68 REMARK 465 THR A 69 REMARK 465 LYS A 70 REMARK 465 PRO A 140 REMARK 465 GLY A 141 REMARK 465 GLY A 555 REMARK 465 ILE A 556 REMARK 465 ARG A 557 REMARK 465 LYS A 558 REMARK 465 VAL A 559 REMARK 465 LEU A 560 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 SER B 3 REMARK 465 PRO B 4 REMARK 465 ILE B 5 REMARK 465 GLU B 89 REMARK 465 VAL B 90 REMARK 465 GLN B 91 REMARK 465 LEU B 92 REMARK 465 GLY B 93 REMARK 465 ILE B 94 REMARK 465 PRO B 95 REMARK 465 THR B 216 REMARK 465 PRO B 217 REMARK 465 ASP B 218 REMARK 465 LYS B 219 REMARK 465 LYS B 220 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 PRO B 225 REMARK 465 PRO B 226 REMARK 465 PHE B 227 REMARK 465 LEU B 228 REMARK 465 TRP B 229 REMARK 465 MET B 230 REMARK 465 GLY B 231 REMARK 465 TYR B 232 REMARK 465 ALA B 360 REMARK 465 HIS B 361 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 465 LYS B 431 REMARK 465 GLU B 432 REMARK 465 PRO B 433 REMARK 465 ILE B 434 REMARK 465 VAL B 435 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 MET A 16 155.97 -41.54 REMARK 500 PRO A 25 120.20 -38.98 REMARK 500 THR A 27 -177.98 -57.58 REMARK 500 GLU A 36 -71.19 -70.37 REMARK 500 GLU A 40 -74.87 -54.11 REMARK 500 ILE A 50 -169.89 -111.18 REMARK 500 GLU A 53 79.36 -162.90 REMARK 500 ASN A 57 129.63 -174.02 REMARK 500 LYS A 64 113.19 -35.53 REMARK 500 ARG A 78 -39.87 -32.22 REMARK 500 GLU A 89 150.37 -35.67 REMARK 500 ASP A 113 81.06 -59.21 REMARK 500 ALA A 114 -64.74 -108.68 REMARK 500 ASP A 121 79.09 -59.75 REMARK 500 GLU A 122 -58.27 -12.66 REMARK 500 PRO A 133 -176.63 -61.48 REMARK 500 ILE A 135 -84.41 -46.69 REMARK 500 GLN A 151 93.37 -62.09 REMARK 500 GLU A 169 -58.79 -20.79 REMARK 500 PRO A 170 -71.07 -57.85 REMARK 500 MET A 184 -130.09 49.49 REMARK 500 SER A 191 -175.36 -170.86 REMARK 500 ASP A 218 -159.19 -78.85 REMARK 500 HIS A 221 -10.12 -150.72 REMARK 500 MET A 230 53.34 29.74 REMARK 500 PRO A 236 0.08 -62.38 REMARK 500 GLN A 242 135.32 -36.10 REMARK 500 THR A 296 -178.07 -62.00 REMARK 500 GLN A 332 43.20 -87.68 REMARK 500 PRO A 345 116.39 -26.51 REMARK 500 PHE A 346 -17.71 77.94 REMARK 500 HIS A 361 117.87 -179.56 REMARK 500 THR A 362 -152.48 -140.85 REMARK 500 PRO A 392 48.69 -78.65 REMARK 500 PRO A 412 178.66 -57.24 REMARK 500 ARG A 461 26.91 -67.66 REMARK 500 LYS A 465 135.35 177.61 REMARK 500 THR A 472 -162.72 -122.34 REMARK 500 ASP A 488 33.87 -73.69 REMARK 500 LEU A 503 -78.88 -44.36 REMARK 500 GLN A 509 71.68 36.26 REMARK 500 LYS A 528 162.66 -49.27 REMARK 500 ALA A 538 -94.94 -48.01 REMARK 500 SER A 553 79.35 -160.54 REMARK 500 PRO B 14 124.56 -31.79 REMARK 500 ASN B 57 139.74 -171.08 REMARK 500 LYS B 65 -90.09 -36.21 REMARK 500 ASP B 67 81.75 58.09 REMARK 500 GLN B 85 174.47 -46.98 REMARK 500 ASN B 137 14.20 50.42 REMARK 500 VAL B 148 -165.47 -126.95 REMARK 500 LYS B 166 -72.83 -47.28 REMARK 500 ILE B 167 -15.22 -48.47 REMARK 500 ASN B 175 77.66 -117.89 REMARK 500 MET B 184 -114.69 52.86 REMARK 500 ARG B 211 48.73 -77.44 REMARK 500 TRP B 212 -61.77 -160.98 REMARK 500 ASP B 237 7.48 -58.79 REMARK 500 ALA B 267 -19.38 -44.37 REMARK 500 ARG B 284 113.14 -32.47 REMARK 500 THR B 286 58.62 -90.80 REMARK 500 LYS B 311 2.12 -58.19 REMARK 500 HIS B 315 159.52 -49.55 REMARK 500 PHE B 346 -4.61 73.42 REMARK 500 LYS B 347 78.94 -111.97 REMARK 500 ARG B 358 132.47 -36.27 REMARK 500 GLN B 407 -1.80 -149.19 REMARK 500 VAL B 423 -30.41 -28.17 REMARK 500 REMARK 500 REMARK: NULL
REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A1002 DISTANCE = 5.06 ANGSTROMS
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NVP A 999
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1VRT RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1RTH RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1VRU RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH ALPHA-APA REMARK 900 RELATED ID: 1RTI RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH HEPT REMARK 900 RELATED ID: 1RTJ RELATED DB: PDB REMARK 900 HIV-1 RT REMARK 900 RELATED ID: 1REV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 9-CL-TIBO REMARK 900 RELATED ID: 1RT1 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH MKC-442 REMARK 900 RELATED ID: 1RT2 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1KLM RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BHAP (U-90152) REMARK 900 RELATED ID: 1RT3 RELATED DB: PDB REMARK 900 AZT DRUG RESISTANT HIV-1 RT MUTANT (RTMC) COMPLEXED WITH REMARK 900 1051U91 REMARK 900 RELATED ID: 1RT4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1RT5 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-10 REMARK 900 RELATED ID: 1RT6 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-38 REMARK 900 RELATED ID: 1RT7 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-84 REMARK 900 RELATED ID: 1C0T RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+21.1326 REMARK 900 RELATED ID: 1C0U RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+50.0934 REMARK 900 RELATED ID: 1C1B RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH GCA-186 REMARK 900 RELATED ID: 1C1C RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-6123 REMARK 900 RELATED ID: 1DTQ RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-1 REMARK 900 RELATED ID: 1DTT RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1EP4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH S-1153 REMARK 900 RELATED ID: 1FK9 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH DMP-226 (EFAVIRENZ) REMARK 900 RELATED ID: 1FKO RELATED DB: PDB REMARK 900 K103N MUTANT HIV-1 RT COMPLEXED WITH DMP-226 (EFAVIRENZ) REMARK 900 RELATED ID: 1FKP RELATED DB: PDB REMARK 900 K103N MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLA RELATED DB: PDB REMARK 900 Y181C MUTANT HIV-1 RT COMPLEXED TNK-651 REMARK 900 RELATED ID: 1JLB RELATED DB: PDB REMARK 900 Y181C MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLC RELATED DB: PDB REMARK 900 Y181C MUTANT HIV-1 RT COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1JLE RELATED DB: PDB REMARK 900 Y188C MUTANT HIV-1 RT REMARK 900 RELATED ID: 1JLF RELATED DB: PDB REMARK 900 Y188C MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLG RELATED DB: PDB REMARK 900 Y188C MUTANT HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1JKH RELATED DB: PDB REMARK 900 Y181C MUTANT HIV-1 RT COMPLEXED WITH DMP-226 (EFAVIRENZ) REMARK 900 RELATED ID: 1JLQ RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 739W94 REMARK 900 RELATED ID: 1LW0 RELATED DB: PDB REMARK 900 T215Y MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1LW2 RELATED DB: PDB REMARK 900 T215Y MUTANT HIV-1 RT COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1LWC RELATED DB: PDB REMARK 900 M184V MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1LWE RELATED DB: PDB REMARK 900 RTMN (M41L+T215Y MUTANT HIV-1 RT) COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1LWF RELATED DB: PDB REMARK 900 RTMQ/M184V (M41L+D67N+K70R+M184V+T215Y MUTANT HIV-1 RT) REMARK 900 COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1S1T RELATED DB: PDB REMARK 900 L100I MUTANT HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1S1U RELATED DB: PDB REMARK 900 L100I MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1S1V RELATED DB: PDB REMARK 900 L100I MUTANT HIV-1 RT COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1S1W RELATED DB: PDB REMARK 900 V106A MUTANT HIV-1 RT COMPLEXED WITH UC-781
DBREF 1S1X A 1 560 UNP P04585 POL_HV1H2 156 715 DBREF 1S1X B 1 440 UNP P04585 POL_HV1H2 156 595
SEQADV 1S1X ILE A 108 UNP P04585 VAL 263 ENGINEERED SEQADV 1S1X CSD A 280 UNP P04585 CYS 435 MODIFIED RESIDUE SEQADV 1S1X ILE B 108 UNP P04585 VAL 263 ENGINEERED
SEQRES 1 A 560 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 560 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 560 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 560 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 560 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 560 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 560 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 560 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 560 SER VAL THR ILE LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 560 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 560 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 560 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 560 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 560 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 560 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 560 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 560 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 560 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 560 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 560 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 560 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 560 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 560 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 560 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 560 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 560 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 560 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 560 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 560 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 560 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 560 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 560 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 560 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 560 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 560 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 560 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 560 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 560 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 560 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 560 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 560 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 560 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY GLY ASN GLU SEQRES 43 A 560 GLN VAL ASP LYS LEU VAL SER ALA GLY ILE ARG LYS VAL SEQRES 44 A 560 LEU SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 440 SER VAL THR ILE LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE
MODRES 1S1X CSD A 280 CYS 3-SULFINOALANINE
HET CSD A 280 8 HET NVP A 999 20
HETNAM CSD 3-SULFINOALANINE HETNAM NVP 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2- HETNAM 2 NVP B:2',3'-E][1,4]DIAZEPIN-6-ONE
HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE HETSYN NVP NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 NVP C15 H14 N4 O FORMUL 4 HOH *21(H2 O)
HELIX 1 1 THR A 27 GLY A 45 1 19 HELIX 2 2 PHE A 77 ARG A 83 1 7 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 ALA A 114 VAL A 118 5 5 HELIX 5 5 ASP A 121 LYS A 126 1 6 HELIX 6 6 GLY A 155 ASN A 175 1 21 HELIX 7 7 GLU A 194 ARG A 211 1 18 HELIX 8 8 THR A 253 TYR A 271 1 19 HELIX 9 9 VAL A 276 LEU A 282 1 7 HELIX 10 10 THR A 296 GLU A 312 1 17 HELIX 11 11 ASN A 363 TRP A 383 1 21 HELIX 12 12 GLN A 394 TYR A 405 1 12 HELIX 13 13 THR A 473 ASP A 488 1 16 HELIX 14 14 SER A 499 ALA A 508 1 10 HELIX 15 15 SER A 515 LYS A 528 1 14 HELIX 16 16 GLY A 544 VAL A 552 1 9 HELIX 17 17 THR B 27 GLU B 44 1 18 HELIX 18 18 PHE B 77 THR B 84 1 8 HELIX 19 19 GLY B 112 VAL B 118 5 7 HELIX 20 20 ASP B 121 LYS B 126 1 6 HELIX 21 21 TYR B 127 ALA B 129 5 3 HELIX 22 22 SER B 134 GLU B 138 5 5 HELIX 23 23 LYS B 154 ASN B 175 1 22 HELIX 24 24 GLU B 194 ARG B 211 1 18 HELIX 25 25 HIS B 235 TRP B 239 5 5 HELIX 26 26 VAL B 254 SER B 268 1 15 HELIX 27 27 VAL B 276 ARG B 284 1 9 HELIX 28 28 THR B 296 LYS B 311 1 16 HELIX 29 29 ASN B 363 GLY B 384 1 22 HELIX 30 30 GLN B 394 TRP B 402 1 9 HELIX 31 31 THR B 403 TYR B 405 5 3 HELIX 32 32 PRO B 420 GLN B 428 1 9
SHEET 1 A 5 ILE A 47 LYS A 49 0 SHEET 2 A 5 ARG A 143 TYR A 146 -1 O GLN A 145 N SER A 48 SHEET 3 A 5 PHE A 130 THR A 131 -1 N PHE A 130 O TYR A 144 SHEET 4 A 5 THR A 58 ILE A 63 1 N THR A 58 O THR A 131 SHEET 5 A 5 ARG A 72 VAL A 75 -1 O LEU A 74 N PHE A 61 SHEET 1 B 3 SER A 105 ILE A 108 0 SHEET 2 B 3 ASP A 186 SER A 191 -1 O VAL A 189 N THR A 107 SHEET 3 B 3 ILE A 178 TYR A 183 -1 N TYR A 183 O ASP A 186 SHEET 1 C 4 PHE A 227 TRP A 229 0 SHEET 2 C 4 TYR A 232 LEU A 234 -1 O TYR A 232 N TRP A 229 SHEET 3 C 4 LYS A 238 VAL A 241 -1 O THR A 240 N GLU A 233 SHEET 4 C 4 HIS A 315 VAL A 317 -1 O GLY A 316 N TRP A 239 SHEET 1 D 5 LYS A 347 TYR A 354 0 SHEET 2 D 5 TRP A 337 GLU A 344 -1 N ILE A 341 O LYS A 350 SHEET 3 D 5 ILE A 326 LYS A 331 -1 N GLN A 330 O THR A 338 SHEET 4 D 5 LYS A 388 LEU A 391 1 O LYS A 390 N ALA A 327 SHEET 5 D 5 TRP A 414 PHE A 416 1 O GLU A 415 N PHE A 389 SHEET 1 E 5 GLN A 464 LEU A 469 0 SHEET 2 E 5 GLY A 453 THR A 459 -1 N GLY A 453 O LEU A 469 SHEET 3 E 5 GLU A 438 ALA A 446 -1 N ALA A 445 O LYS A 454 SHEET 4 E 5 GLU A 492 THR A 497 1 O ASN A 494 N PHE A 440 SHEET 5 E 5 LYS A 530 TRP A 535 1 O ALA A 534 N ILE A 495 SHEET 1 F 3 ILE B 47 LYS B 49 0 SHEET 2 F 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 F 3 PHE B 130 ILE B 132 -1 N PHE B 130 O TYR B 144 SHEET 1 G 2 VAL B 60 ILE B 63 0 SHEET 2 G 2 ARG B 72 VAL B 75 -1 O LEU B 74 N PHE B 61 SHEET 1 H 3 SER B 105 ASP B 110 0 SHEET 2 H 3 ASP B 186 SER B 191 -1 O VAL B 189 N THR B 107 SHEET 3 H 3 VAL B 179 TYR B 183 -1 N TYR B 181 O TYR B 188 SHEET 1 I 2 TRP B 252 THR B 253 0 SHEET 2 I 2 VAL B 292 ILE B 293 -1 O ILE B 293 N TRP B 252 SHEET 1 J 5 LYS B 347 TYR B 354 0 SHEET 2 J 5 GLN B 336 GLU B 344 -1 N ILE B 341 O LYS B 350 SHEET 3 J 5 ILE B 326 GLY B 333 -1 N ILE B 326 O TYR B 342 SHEET 4 J 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 J 5 TRP B 414 PHE B 416 1 O GLU B 415 N LEU B 391
LINK C LEU A 279 N CSD A 280 1555 1555 1.33 LINK C CSD A 280 N LYS A 281 1555 1555 1.33
CISPEP 1 PRO A 225 PRO A 226 0 0.15 CISPEP 2 PRO A 420 PRO A 421 0 -0.25
SITE 1 AC1 10 LEU A 100 LYS A 101 VAL A 106 VAL A 179 SITE 2 AC1 10 TYR A 181 TYR A 188 GLY A 190 PHE A 227 SITE 3 AC1 10 TRP A 229 TYR A 318
CRYST1 138.400 109.000 72.800 90.00 90.00 90.00 P 21 21 21 4
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.007225 0.000000 0.000000 0.00000
SCALE2 0.000000 0.009174 0.000000 0.00000
SCALE3 0.000000 0.000000 0.013736 0.00000